Breast cancer predisposing alleles in Poland

被引:113
作者
Górski, B
Cybulski, C
Huzarski, T
Byrski, T
Gronwald, J
Jakubowska, A
Stawicka, M
Gozdecka-Grodecka, S
Szwiec, M
Urbañski, K
Mitus, J
Marczyk, E
Dziuba, J
Wandzel, P
Surdyka, D
Haus, O
Janiszewska, H
Debniak, T
Toloczko-Grabarek, A
Medrek, K
Masojc, B
Mierzejewski, M
Kowalska, E
Narod, SA
Lubinski, J
机构
[1] Pomeranian Med Acad, Dept Genet & Pathol, Int Hereditary Canc Ctr, PL-70115 Szczecin, Poland
[2] Prophylact & Epidemiol Ctr, Poznan, Poland
[3] Poznan Med Univ, Poznan, Poland
[4] Reg Oncol Hosp, Opole, Poland
[5] Reg Oncol Ctr, Krakow, Poland
[6] Reg Oncol Hosp, Bielsko Biala, Poland
[7] Reg Oncol Hosp, Lublin, Poland
[8] Univ Toronto, Ctr Res Womens Hlth, Toronto, ON, Canada
关键词
BRCA1; CHEK2; NBS1; breast cancer;
D O I
10.1007/s10549-005-1409-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutant alleles of several genes in the DNA repair pathway have been found to predispose women to breast cancer. From a public health perspective, the importance of a given allele in a population is determined by the frequency of the allele and by the relative risk of breast cancer that it confers. In Poland founder alleles of the BRCA1, CHEK2 and NBS1 genes have been associated with an increased risk of breast cancer, but the relative contribution of each of these alleles to the overall breast cancer burden has not yet been determined. We screened 2012 unselected cases of breast cancer and 4000 population controls for 7 different mutations in these genes. Overall, a mutation was found in 12% of the cases and in 6% of the controls. Mutations in BRCA1 and CHEK2 contributed in approximately equal measure to the burden of breast cancer in Poland. A BRCA1 mutation was present in 3% of the cases. The missense BRCA1 mutation C61G was associated with a higher odds ratio for breast cancer (OR=15) than were either of the truncating BRCA1 mutations 4153delA (OR=2.0) and 5382insC (OR=6.2). In contrast, a higher odds ratio was seen for truncating CHEK2 mutations (OR=2.1) than for the missense mutation I157T (OR=1.4). This study suggests that cancer risks may be specific for particular alleles of a susceptibility gene and that these different risks should be taken into account by genetic counselors.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 13 条
[1]   Novel founder CHEK2 mutation is associated with increased prostate cancer risk [J].
Cybulski, C ;
Huzarski, T ;
Górski, B ;
Masojc, B ;
Mierzejewski, M ;
Debniak, T ;
Gliniewicz, B ;
Matyjasik, J ;
Zlowocka, E ;
Kurzawski, G ;
Sikorski, A ;
Posmyk, M ;
Szwiec, M ;
Czajka, R ;
Narod, SA ;
Lubinski, J .
CANCER RESEARCH, 2004, 64 (08) :2677-2679
[2]  
CYBULSKI C, 2004, IN PRESS CANC RES
[3]   Founder mutations in the BRCA1 gene in polish families with breast-ovarian cancer [J].
Górski, B ;
Byrski, T ;
Huzarski, T ;
Jakubowska, A ;
Menkiszak, J ;
Gronwald, J ;
Pluzanska, A ;
Bebenek, M ;
Fischer-Maliszewska, L ;
Grzybowska, E ;
Narod, SA ;
Lubinski, J .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (06) :1963-1968
[4]   Germline 657del5 mutation in the NBS1 gene in breast cancer patients [J].
Górski, B ;
Debniak, T ;
Masoic, B ;
Mierzejewski, M ;
Medrek, K ;
Cybulski, C ;
Jakubowska, A ;
Kurzawski, G ;
Chosia, M ;
Scott, R ;
Lubinski, J .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (03) :379-381
[5]   A high proportion of founder BRCA1 mutations in Polish breast cancer families [J].
Górski, B ;
Jakubowska, A ;
Huzarski, T ;
Byrski, T ;
Gronwald, J ;
Grzybowska, E ;
Mackiewicz, A ;
Stawicka, M ;
Bebenek, M ;
Sorokin, D ;
Fiszer-Maliszewska, L ;
Haus, O ;
Janiszewska, H ;
Niepsuj, S ;
Gózdz, S ;
Zaremba, L ;
Posmyk, M ;
Pluzanska, M ;
Kilar, E ;
Czudowska, D ;
Wasko, B ;
Miturski, R ;
Kowalczyk, JR ;
Urbanski, K ;
Szwiec, M ;
Koc, J ;
Debniak, B ;
Rozmiarek, A ;
Debniak, T ;
Cybulski, C ;
Kowalska, E ;
Toloczko-Grabarek, A ;
Zajaczek, S ;
Menkiszak, J ;
Medrek, K ;
Masojc, B ;
Mierzejewski, M ;
Narod, SA ;
Lubinski, J .
INTERNATIONAL JOURNAL OF CANCER, 2004, 110 (05) :683-686
[6]  
Johannesdottir G, 1996, CANCER RES, V56, P3663
[7]  
MASOJC B, 2001, INT C STUD YOUNG PHY
[8]   Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations [J].
Meijers-Heijboer, H ;
van den Ouweland, A ;
Klijn, J ;
Wasielewski, M ;
de Snoo, A ;
Oldenburg, R ;
Hollestelle, A ;
Houben, M ;
Crepin, E ;
van Veghel-Plandsoen, M ;
Elstrodt, F ;
van Duijn, C ;
Bartels, C ;
Meijers, C ;
Schutte, M ;
McGuffog, L ;
Thompson, D ;
Easton, DF ;
Sodha, N ;
Seal, S ;
Barfoot, R ;
Mangion, J ;
Chang-Claude, J ;
Eccles, D ;
Eeles, R ;
Evans, DG ;
Houlston, R ;
Murday, V ;
Narod, S ;
Peretz, T ;
Peto, J ;
Phelan, C ;
Zhang, HX ;
Szabo, C ;
Devilee, P ;
Goldgar, D ;
Futreal, PA ;
Nathanson, KL ;
Weber, BL ;
Rahman, N ;
Stratton, MR .
NATURE GENETICS, 2002, 31 (01) :55-59
[9]   Hereditary ovarian cancer in Poland [J].
Menkiszak, J ;
Gronwald, J ;
Górski, B ;
Jakubowska, A ;
Huzarski, T ;
Byrski, T ;
Foszczynska-Kloda, M ;
Haus, O ;
Janiszewska, H ;
Perkowska, M ;
Brozek, I ;
Grzybowska, E ;
Zientek, H ;
Gózdz, S ;
Kozak-Klonowska, B ;
Urbanski, K ;
Miturski, R ;
Kowalczyk, J ;
Pluzanska, A ;
Niepsuj, S ;
Koc, J ;
Szwiec, M ;
Drosik, K ;
Mackiewicz, A ;
Lamperska, K ;
Strózyk, E ;
Godlewski, D ;
Stawicka, M ;
Wasko, B ;
Bebenek, M ;
Rozmiarek, A ;
Rzepka-Górska, I ;
Narod, SA ;
Lubinski, J .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (06) :942-945
[10]  
Offit Kenneth, 2003, BMC Med Genet, V4, P1, DOI 10.1186/1471-2350-4-1